Photo-regulated PROTACs: A novel tool for temporal control of targeted protein degradation
Bioorganic & Medicinal Chemistry Letters · 2024
DOI: 10.1016/j.bmcl.2024.129778 ↗Kurz gefasst
Fachartikel in der Zeitschrift Bioorganic & Medicinal Chemistry Letters, 2024. Verfasst von Hanqiao Xu und 4 weiteren Autor:innen. Beteiligte Einrichtung: Graduate School of Medical Life Science, Yokohama City University, 1-7-29, Yokohama, Kanagawa 230-0045, Japan; Division of Organic Chemistry, Nationa…. Hauptthemen laut MEDLINE: Proteolysis, Transcription Factors, Ultraviolet Rays, Cell Cycle Proteins. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 22 Literaturangaben. Gefördert von: University Fellowship Creation Project for Creating Scientific and Technological Innovation, Japan Society for the Promotion of Science, Kowa Life Science Foundation.
Abstract (Originalsprache)
PROTACs (Proteolysis targeting chimeras) are chimeric molecules designed to induce targeted protein degradation via the ubiquitin-proteasome system. These molecules catalytically degrade target proteins and sustainably inhibit their function. Therefore, PROTAC's unique mechanism of action is not only beneficial in medicine but also serves as a valuable tool for molecular biological analysis in fields like chemical biology, biochemistry, and drug discovery. This study presents a novel turn-off (ON-OFF) type PROTAC development strategy utilizing a photocleavable linker. The inclusion of this linker enables temporal control of the degradation activity targeting BRD4 protein upon UV light exposure. PROTAC-2 demonstrated the most potent degradation activity against BRD4 among the other synthesized PROTACs with varying linker lengths. The UV light-induced cleavage of PROTAC-2 was confirmed, leading to a reduction in its BRD4 degradation activity. Notably, this study introduces a novel linker capable of nullifying degradation activity of PROTACs which is activated by light irradiation. These findings offer a promising strategy for the development of turn-off type PROTACs, providing enhanced temporal control over protein degradation. The approach holds significant potential for applications in molecular function studies and drug discovery.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Graduate School of Medical Life Science, Yokohama City University, 1-7-29, Yokohama, Kanagawa 230-0045, Japan; Division of Organic Chemistry, National Institute of Health Sciences, 3-25-26, Tonomachi, Kawasaki, Kanagawa…
- Division of Molecular Target and Gene Therapy Products, National Institute of Health Sciences, 3-25-26, Tonomachi, Kawasaki, Kanagawa 210-9501, Japan. Electronic address: n-ohoka@nihs.go.jp.
- Division of Molecular Target and Gene Therapy Products, National Institute of Health Sciences, 3-25-26, Tonomachi, Kawasaki, Kanagawa 210-9501, Japan.
- Division of Organic Chemistry, National Institute of Health Sciences, 3-25-26, Tonomachi, Kawasaki, Kanagawa 210-9501, Japan. Electronic address: yokoo@nihs.go.jp.
Förderung
- University Fellowship Creation Project for Creating Scientific and Technological Innovation
- Japan Society for the Promotion of Science
- Kowa Life Science Foundation
- AMED
- Takeda Science Foundation
- JST
- ACT-X
Zitieren
APA
Xu, H., Ohoka, N., Inoue, T., Yokoo, H., & Demizu, Y. (2024). Photo-regulated PROTACs: A novel tool for temporal control of targeted protein degradation. Bioorganic & Medicinal Chemistry Letters. https://doi.org/10.1016/j.bmcl.2024.129778
Vancouver
Xu H, Ohoka N, Inoue T, Yokoo H, Demizu Y. Photo-regulated PROTACs: A novel tool for temporal control of targeted protein degradation. Bioorganic & Medicinal Chemistry Letters. 2024. doi:10.1016/j.bmcl.2024.129778
BibTeX
@article{Xu2024,
author = {Xu, Hanqiao and Ohoka, Nobumichi and Inoue, Takao and Yokoo, Hidetomo and Demizu, Yosuke},
title = {Photo-regulated PROTACs: A novel tool for temporal control of targeted protein degradation},
journal = {Bioorganic & Medicinal Chemistry Letters},
year = {2024},
doi = {10.1016/j.bmcl.2024.129778}
}
EUVIMED